Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The adolescence of cancer immunotherapy: from adifficult childhood to apillar of modern anticancer therapy

The adolescence of cancer immunotherapy: from adifficult childhood to apillar of modern... editorial memo (2018) 11:82–83 https://doi.org/10.1007/s12254-018-0412-2 The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy Thorsten Fuereder Received: 4 May 2018 / Accepted: 9 May 2018 / Published online: 24 May 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Cancer immunotherapy was born in the 1890s and became standard of care and the preferred treatment raised by its father William Coley, who provoked an option in a variety of malignancies: in metastatic immune response by injecting a mixture of different melanoma, which is regarded as almost unrespon- bacteria into patients suffering from a variety of sarco- sive to dacarbazine chemotherapy, the Checkmate mas. Although impressive responses were observed, 066 and 067 trials set a new gold standard for this the efficacy of Coley’s toxin was unpredictable and disease with a 3-year overall survival (OS) rate of 58% lethal side effects occurred. Therefore, immunother- in the ipilimumab/nivolumab combination arm [2]. apy was shelved for several decades and alternative Likewise, in metastatic non-small cell lung cancer concepts such as radiation or chemotherapy were (NSCLC) long-term survival can be achieved by im- preferred. With the advent of molecular oncology, munotherapy. Very recently, the Keynote http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

The adolescence of cancer immunotherapy: from adifficult childhood to apillar of modern anticancer therapy

Loading next page...
 
/lp/springer-journals/the-adolescence-of-cancer-immunotherapy-from-adifficult-childhood-to-rqQV1LRNS1

References (4)

  • L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)

    Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

    The New England Journal of Medicine, 378

  • S. Maude, T. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. Verneris, H. Stefanski, G. Myers, M. Qayed, B. Moerloose, H. Hiramatsu, Krysta Schlis, K. Davis, P. Martin, Eneida Nemecek, G. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. June, B. Levine, P. Wood, T. Taran, M. Leung, K. Mueller, Yiyun Zhang, K. Sen, D. Lebwohl, M. Pulsipher, S. Grupp (2018)

    Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

    The New England Journal of Medicine, 378

  • J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, C. Cowey, C. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. Ferrucci, A. Hill, J. Wagstaff, M. Carlino, J. Haanen, M. Maio, I. Márquez-Rodas, G. McArthur, P. Ascierto, G. Long, M. Callahan, M. Postow, M. Postow, K. Grossmann, M. Sznol, B. Dréno, L. Bastholt, A. Yang, L. Rollin, C. Horak, F. Hodi, J. Wolchok, J. Wolchok (2015)

    Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    The New England journal of medicine, 373 1

  • Jun Tang, A. Shalabi, Vanessa Hubbard-Lucey (2018)

    Comprehensive analysis of the clinical immuno-oncology landscape

    Annals of Oncology, 29

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-018-0412-2
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2018) 11:82–83 https://doi.org/10.1007/s12254-018-0412-2 The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy Thorsten Fuereder Received: 4 May 2018 / Accepted: 9 May 2018 / Published online: 24 May 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Cancer immunotherapy was born in the 1890s and became standard of care and the preferred treatment raised by its father William Coley, who provoked an option in a variety of malignancies: in metastatic immune response by injecting a mixture of different melanoma, which is regarded as almost unrespon- bacteria into patients suffering from a variety of sarco- sive to dacarbazine chemotherapy, the Checkmate mas. Although impressive responses were observed, 066 and 067 trials set a new gold standard for this the efficacy of Coley’s toxin was unpredictable and disease with a 3-year overall survival (OS) rate of 58% lethal side effects occurred. Therefore, immunother- in the ipilimumab/nivolumab combination arm [2]. apy was shelved for several decades and alternative Likewise, in metastatic non-small cell lung cancer concepts such as radiation or chemotherapy were (NSCLC) long-term survival can be achieved by im- preferred. With the advent of molecular oncology, munotherapy. Very recently, the Keynote

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: May 24, 2018

There are no references for this article.